Literature DB >> 17116332

Invasive group A streptococcal infection in injecting drug users and non-drug users in a single UK city.

S J Curtis1, A Tanna, H H Russell, A Efstratiou, J Paul, M Cubbon, S Sriskandan.   

Abstract

OBJECTIVES: Injecting drug users (IDU) represent an increasing proportion of patients with invasive group A streptococcal (GAS) disease. Our aims were to characterise the clinical presentation and strains causing GAS bacteremia in IDU from a single UK city (Brighton and Hove), and to compare this patient group with non-drug users (non-DU) with GAS bacteremia.
METHODS: Consecutive GAS blood culture isolates from twenty-two IDU and twenty-two non-DU presenting to the city hospital were studied. Clinical features, strain emm typing and superantigen toxin genotyping were investigated.
RESULTS: GAS invasive disease presented differently in IDU compared to non-DU with a predominance of injection site abscesses and lower mortality in IDU. GAS strains from IDU were predominantly emm82 and emm83 types, which are uncommon in the UK and emm82 strains appeared clonal. The non-DU GAS strains demonstrated a broader range of emm types including most frequently emm1 and emm89. There was no major difference in superantigen gene profile between the isolate groups.
CONCLUSION: The distinct presentation of invasive GAS disease in IDU compared with non-DU was associated with distinct emm types, a predominance of abscesses, and low mortality, although the small numbers preclude definitive conclusions. Further study is required to establish if these findings reflect strain differences or epidemiological differences in colonisation patterns and injecting practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116332     DOI: 10.1016/j.jinf.2006.10.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998-2009): comparison with non-invasive isolates.

Authors:  M Montes; C Ardanuy; E Tamayo; A Domènech; J Liñares; E Pérez-Trallero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

Review 2.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

3.  Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection.

Authors:  Claire E Turner; Prathiba Kurupati; Michael D Jones; Robert J Edwards; Shiranee Sriskandan
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

4.  Ongoing outbreak of invasive and non-invasive disease due to group A Streptococcus (GAS) type emm66 among homeless and people who inject drugs in England and Wales, January to December 2016.

Authors:  Nick Bundle; Laura Bubba; Juliana Coelho; Rachel Kwiatkowska; Rachel Cloke; Sarah King; Jill Rajan-Iyer; Max Courtney-Pillinger; Charles R Beck; Vivian Hope; Theresa Lamagni; Colin S Brown; Daiga Jermacane; Rachel Glass; Monica Desai; Maya Gobin; Sooria Balasegaram; Charlotte Anderson
Journal:  Euro Surveill       Date:  2017-01-19

5.  Prevalent emm Types among Invasive GAS in Europe and North America since Year 2000.

Authors:  Giovanni Gherardi; Luca Agostino Vitali; Roberta Creti
Journal:  Front Public Health       Date:  2018-03-09

6.  Superantigenic activity of emm3 Streptococcus pyogenes is abrogated by a conserved, naturally occurring smeZ mutation.

Authors:  Claire E Turner; Mary Sommerlad; Karen McGregor; Frances J Davies; Bruno Pichon; Deborah L W Chong; Leili Farzaneh; Matthew T G Holden; Brian G Spratt; Androulla Efstratiou; Shiranee Sriskandan
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

7.  Invasive group A streptococcal infection outbreaks of typeemm118 in a long-term care facility, and of type emm74 in the homeless population, Montréal, Quebec.

Authors:  P A Pilon; N Savard; J Aho; J Caron; A Urbanek; R Paré; P Le Guerrier; C Savard; K Hammond-Collins; C Dung Tran; R Allard; M C Domingo
Journal:  Can Commun Dis Rep       Date:  2019-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.